Craniopharyngioma With Tumoral Hemorrhage

Craniopharyngioma Clinical Trial

Official title:

Clinical Features and Risk Factors of Craniopharyngioma With Tumoral Hemorrhage

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04937335
• Other study ID #: kaishu1
• Status: Completed
• Start date: January 1, 2013
• Est. completion date: February 1, 2021

Study information

• Verified date: June 2021
• Source: Tongji Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Clinical data of 185 consecutive patients receiving resective operation with a pathological diagnosis of craniopharyngioma in our hospital between January 2013 and February 2021 were collected. Among these patients, 18 of them were recognized as craniopharyngioma with tumoral hemorrhage during the operation.

Description:

For each case, age, gender, smoking status, alcohol intake, past history, symptoms, blood pressure, blood cell count, blood biochemical tests, coagulation tests, hormone tests, radiological results, surgical treatment and the outcome at discharge were collected. The first test result after admission and before the operation was taken for the items of blood tests with multiple times in the analysis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 185
• Est. completion date: February 1, 2021
• Est. primary completion date: February 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• receive resective operation with a pathological diagnosis of craniopharyngioma in our hospital

• enter our hospital between January 2013 and February 2021

Exclusion Criteria:

• have a non-craniopharyngioma or unverified pathological diagnosis at discharge

• have received surgical or radiological treatment on the sellar region

• receive treatment of coagulation modulation, immunosuppressive agents or chemotherapeutic drugs

• combine with other clinical emergencies including acute myocardial infarction, cerebral stroke, trauma and sepsis at admission

• have been diagnosed with other tumors, hematological diseases, autoimmune diseases, liver failure or renal failure

Related Conditions & MeSH terms

• Apoplexy
• Craniopharyngioma
• Hemorrhage

Intervention

Other:
• intratumoral hemorrhage
Patients who were recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation were enrolled in the hemorrhage group.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Tongji Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	craniopharyngioma with tumoral hemorrhage	Current study is a case-control study whose primary outcome is tumoral hemorrhage observed during the operation, which devided the craniopharyngioma patients into hemorrhage group and non-hemorrhage group.	during the operation